Workflow
毕得医药(688073) - 2022 Q4 - 年度财报

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 145,970,727.07, with the parent company reporting a net profit of RMB 93,801,072.91[5]. - The proposed cash dividend is RMB 15.40 per 10 shares (including tax), totaling RMB 99,971,243.68, which represents 68.49% of the annual net profit attributable to shareholders[5]. - The company's operating revenue for 2022 was CNY 833.83 million, representing a 37.55% increase compared to CNY 606.22 million in 2021[26]. - The net profit attributable to shareholders for 2022 was CNY 145.97 million, a 49.60% increase from CNY 97.57 million in 2021[26]. - The basic earnings per share for 2022 was CNY 2.77, up 35.78% from CNY 2.04 in 2021[27]. - The total assets at the end of 2022 were CNY 2.36 billion, a 160.36% increase from CNY 906.13 million at the end of 2021[26]. - The company's R&D expenditure as a percentage of operating revenue was 5.53% in 2022, slightly down from 5.75% in 2021[27]. - The cash flow from operating activities for 2022 was CNY 29.87 million, a significant recovery from a negative cash flow of CNY 64.88 million in 2021[26]. - The weighted average return on equity for 2022 was 14.24%, down from 18.15% in 2021, indicating a decrease of 3.91 percentage points[27]. - The net assets attributable to shareholders increased to CNY 2.08 billion at the end of 2022, a 230.15% increase from CNY 628.86 million at the end of 2021[26]. Research and Development - The company provided comprehensive drug research and development services for global pharmaceutical companies and biopharmaceutical research institutions[14]. - The company focuses on the discovery, development, and commercialization of innovative molecular targeted immunotherapy drugs for cancer treatment[14]. - The company emphasizes the importance of drug molecular building blocks in designing and synthesizing candidate active drug molecules[14]. - The company is engaged in the research and development of new drugs, including the discovery of drug targets and the screening of lead compounds[15]. - The company aims to optimize lead compounds to meet safety and efficacy requirements for new drug development[15]. - The company is involved in preclinical research, which includes chemical synthesis and pharmacological studies[15]. - The company highlights the significance of drug targets in modern new drug development[15]. - The company is committed to developing innovative drugs with independent intellectual property rights[15]. - The company has the capability to provide over 400,000 novel and diverse drug molecular blocks, with a stock of over 86,000 types readily available[37]. - The R&D team expanded to 168 members, with R&D expenses amounting to 46.07 million yuan, reflecting a 32.08% increase year-on-year[40]. Market Expansion and Strategy - The company aims to continue expanding its market presence and investing in new product development to drive future growth[19]. - The company aims to become a leading enterprise in the global molecular block field, actively expanding its presence in the U.S., Europe, and India[43]. - The company plans to enhance inventory management efficiency and expand its global business scale to support new drug development[28]. - The company is exploring partnerships with international firms to enhance its global footprint and leverage new technologies[146]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential deals[148]. - The company plans to develop high-quality serum products as a breakthrough in the life sciences and biopharmaceutical fields[122]. - The company is focusing on the independent research and development of boron-containing drug molecular building blocks, aiming to enhance brand awareness and open overseas markets[129]. Corporate Governance - The board of directors and senior management have confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not disclosed any special arrangements for corporate governance[8]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation of the shareholders' meeting, board of directors, and supervisory board[179]. - The company adheres to strict information disclosure obligations, ensuring timely and accurate communication with investors[135]. - The company held two shareholder meetings in 2022, ensuring compliance with legal procedures and allowing all shareholders to exercise their voting rights[134]. - The company has not reported any changes in shareholding for key executives during the reporting period[140]. - The company has maintained a stable leadership team with no new appointments or departures reported during the year[140]. Environmental and Social Responsibility - The company emphasizes the importance of ESG (Environmental, Social, and Governance) management, integrating it into overall strategy and operations[183]. - The company invested ¥2.1525 million in environmental protection during the reporting period[184]. - The company has established an environmental management system compliant with ISO14001:2015 standards[190]. - The company is not classified as a key pollutant discharge unit and operates in the "M73 Research and Experimental Development" industry, which is not heavily polluting[185]. - There were no administrative penalties received due to environmental issues during the reporting period[186]. Risks and Challenges - The company has outlined various risks and countermeasures in its report, emphasizing the importance of investor awareness regarding investment risks[4]. - The company faces risks related to talent retention and product quality control, which could impact future performance[84][86].